Nvidia stomps the bears. Plus, Cramer's thoughts on 2 struggling portfolio names

Nvidia stomps the bears. Plus, Cramer's thoughts on 2 struggling portfolio names


Jensen Huang, co-founder and chief executive officer of Nvidia Corp., arrives at an event in Taipei, Taiwan, on Thursday, Jan. 25, 2024.

Lam Yik Fei | Bloomberg | Getty Images

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)



Source

Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know
Health

Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food and Drug Administration may add its strongest safety warning to Covid shots – marking another major shift in vaccine oversight.  It could also expand a […]

Read More
‘The next protein’: Fiber is shaping up to be the latest grocery obsession
Health

‘The next protein’: Fiber is shaping up to be the latest grocery obsession

Workers are suspended on a Pepsi sign on a building outside of Allegiant Stadium ahead of LVIII in Las Vegas, Nevada, U.S., February 9, 2024. Brian Snyder | Reuters One of this year’s top food trends is facing some tough competition. Protein captivated consumers and food companies in 2025, but fiber is increasingly stealing the […]

Read More
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Health

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]

Read More